– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation – – Continuous daily dosing well tolerated and with manageable safety profile to date –
Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH SAN DIEGO , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunity for tipifarnib plus PI3Kα inhibitor in HRAS-
SAN DIEGO , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming virtual
SAN DIEGO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3Kα inhibitor in relapsed/refractory HNSCC – SAN DIEGO
– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – SAN DIEGO , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today
SAN DIEGO , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
SAN DIEGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale , M.D., as Chief Medical Officer. Dr.
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to expand to HRAS and PI3K dependent tumors with potential to target up to 50% of HNSCC – – $338.9 million
